作为GLP-1受体激动剂,塞马格卢提德可以降低食欲,同时增加多巴胺奖励信号传递
Karlijn L Kooij1,2, Derek IJsbrand Koster1, Emma Eeltink1
1UMC Brain Center, Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht University, the Netherlands.
Neuroscience applied
|July 14, 2025
概括
塞马格卢提德减少了食物摄入量和奖励收集,同时增加了食物消费期间大脑奖励中心的多巴胺活性. 这表明对食欲和奖励通路有复杂的影响.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 代谢研究研究 代谢研究
背景情况:
- 作为GLP-1受体激动剂的塞马格卢提德 (semaglutide) 已知可以减肥,并降低对美味食物的动机.
- 塞马格卢提德对食物奖励处理的影响背后的精确神经机制尚未完全理解.
研究的目的:
- 调查塞马格卢提德对寻求奖励行为的影响以及在腹部体区域 (VTA) 的多巴胺神经元活动.
- 探索塞马格卢提德如何影响多巴胺信号,以响应线索和实际的奖励交付.
主要方法:
- 使用Pitx3-cre小鼠与VTA GCaMP6s病毒注射进行*in vivo*纤维光度测量以监测多巴胺神经元活动.
- 采用了帕夫洛夫式的糖调节范式,其中一个提示预测了糖奖励的交付.
- 在任务期间,以评估行为和神经反应,通过腹膜内注射塞马格卢提德或载体.
主要成果:
- 一个1毫克/公斤的塞马格卢提德剂量降低了奖励收集和行为.
- 在糖收集期间,塞马格卢提德显著增加了VTA多巴胺神经元活动,但在提示呈现期间没有.
- 较低的赛马格卢提德剂量 (0.1-0.3 mg/kg) 减少了食摄入量,但没有影响糖摄入量或VTA多巴胺活性.
结论:
- 塞马格卢提德调节食欲并增强VTA多巴胺信号,特别是在奖励的消费期间.
- 药物对多巴胺信号传递的影响取决于上下文,发生在奖励摄入期间,而不是在预测性暗示暴露期间.
相关概念视频
Glucagon-like Receptor Agonists
424
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
424
Regulation of Food Intake
484
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
484
Dipeptidyl Peptidase 4 Inhibitors
262
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
262
Oral Hypoglycemic Agents: Glinides
268
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
268
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
409
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
409
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
628
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
628


